During the past decade, Instituto Alexander fleming conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 21 clinical trials were completed, i.e. on average, 56.8% percent of trials that started reached the finish line to date. In the past 5 years, 27 clinical trials started and 11 clinical trials were completed. i.e. 40.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Instituto Alexander fleming" #1 sponsor was "Hoffmann-La Roche" with 10 trials, followed by "Pfizer" with 8 trials sponsored, "Bristol-Myers Squibb" with 4 trials sponsored, "EMD Serono Research & Development Institute, Inc." with 4 trials sponsored and "Astellas Pharma Inc" with 4 trials sponsored. Other sponsors include 29 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Instituto Alexander fleming" #1 collaborator was "Merck KGaA, Darmstadt, Germany" with 4 trials as a collaborator, "Amsterdam UMC, location VUmc" with 3 trials as a collaborator, "Hospital Central del IPS" with 3 trials as a collaborator, "INSTITUTO ALEXANDER FLEMING" with 3 trials as a collaborator and "IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto" with 3 trials as a collaborator. Other collaborators include 41 different institutions and companies that were collaborators in the rest 39 trials.

According to Clinical.Site data, the most researched conditions in "Instituto Alexander fleming" are "Melanoma" (7 trials), "Carcinoma, Non-Small-Cell Lung" (3 trials), "Gastric Cancer" (3 trials), "Pancreatic Cancer" (3 trials) and "Aspergillosis" (2 trials). Many other conditions were trialed in "Instituto Alexander fleming" in a lesser frequency.

Most popular intervention types in "Instituto Alexander fleming" are "Drug" (56 trials), "Biological" (12 trials), "Other" (4 trials) and "Radiation" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Cisplatin" (7 trials), "Pembrolizumab" (6 trials), "Gemcitabine" (5 trials) and "Atezolizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Instituto Alexander fleming" are 54 trials for "All" genders, 5 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Instituto Alexander fleming". undefined are not yet recruiting, 15 are recruiting, 13 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 26 completed trials in Instituto Alexander fleming, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Instituto Alexander fleming, 3 "Phase 1" clinical trials were conducted, 10 "Phase 2" clinical trials and 48 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".